Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy.
Brachytherapy is a form of radiotherapy that treats cancer by irradiation from a short distance. Two different forms of brachytherapy are used today: permanent and temporary brachytherapy. In permanent brachytherapy, a small radioactive source is implanted in the body, while in temporary brachytherapy, the radioactive source is placed directly inside or close to the site of the tumor for a limited and defined period.
Eckert & Ziegler BEBIG has acquired the brachytherapy business of Biocompatibles Inc. as well as Mick Radio-Nuclear Instruments, Inc..
Eckert & Ziegler BEBIG offers a complete portfolio of brachytherapy products, which comprises the HDR afterloader, MultiSource®, the permanent prostate implants so called seeds in a loose (IsoSeed® and AnchorSeed®) and stranded form (IsoCord®), as well as ophthalmic applicators for the treatment of eye tumors. Eckert & Ziegler BEBIG is also the only provider worldwide of the miniaturized cobalt Co-60 source used in the HDR afterloading systems.
The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
2nd ICMPROI combined with the 3rd Annual Conference of the BMPS
August 20-22, 2014